Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04661215
Other study ID # 12 DK PSAGS
Secondary ID U24DK074008U01DK
Status Not yet recruiting
Phase
First received
Last updated
Start date July 30, 2024
Est. completion date December 2026

Study information

Verified date May 2024
Source Johns Hopkins Bloomberg School of Public Health
Contact Laura A Miriel, BS
Phone 410-955-4165
Email laura.miriel@jhu.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The overall objective of this study is to determine if there are pyloric sphincter abnormalities in patients with gastroparesis symptoms and determine how prevalent these abnormalities are using tests to assess the pyloric sphincter - endoluminal functional luminal imaging probe (Endoflip™), water load satiety testing (WLST), and high-resolution cutaneous electrogastrography (HR-EGG) using Gastric Alimetry™ System.


Description:

Study Description: This is a multi-center, prospective, observational study to assess pyloric sphincter abnormalities in patients with symptoms of gastroparesis (both delayed and normal gastric emptying) and control participants without symptoms of gastroparesis using the commercially available, FDA approved endoluminal functional luminal imaging probe (Endoflip™) catheter, which measures diameter, cross-sectional area, pressure, compliance, and distensibility of gastrointestinal sphincter muscles. This study will assess lower esophageal and pyloric sphincter diameter, CSA, pressure, distensibility, and compliance in patients with symptoms of gastroparesis and delayed gastric emptying, patients with symptoms of gastroparesis but with normal gastric emptying, and normal control participants. The protocol will also include a water load satiety test and use Gastric Alimetry™ System that assesses gastric myoelectrical activity in symptomatic participants but not control participants.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date December 2026
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria FOR SYMPTOMATIC PARTICIPANTS: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 18-85 4. Symptoms of gastroparesis, either diabetic or idiopathic etiology 5. Symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0 (18/45 x 5) 6. Individual will have had a prior 4-hour gastric emptying scintigraphy test performed for clinical evaluation within the last 6 months. This gastric emptying test would be done for clinical evaluation and is not part of the research study. From these participants with gastroparesis symptoms, we will include those with delayed gastric emptying as well as those with normal gastric emptying. 7. Participant must not initiate any new treatments until completion of the study procedures. 8. Willingness to: 1. Stop histamine 2 antagonists, prokinetics (e.g., metoclopramide, erythromycin, domperidone, prucalopride), narcotics, anticholinergics, constipation medications (over the counter laxatives, isotonic polyethylene glycol (PEG) electrolyte preparations (e.g. MiraLax), prescription laxatives (e.g. lubiprostone), proton pump inhibitors, cannabinoids, and cannabidiol (CBD) for 3 days prior to each visit; 2. Abstain from food and water after midnight (at least for 8 hours) before the start of each visit until after the visit. INCLUSION CRITERIA FOR CONTROL PARTICIPANTS 1. Provision of signed and dated informed consent form 2. Male or female, aged 18 or older 3. Undergoing an upper endoscopy for their clinical evaluation of diarrhea, GI bleed, or iron-deficiency anemia, or evaluation for bariatric surgery. 4. Do not have upper GI symptoms greater than 1 as assessed by the Gastroparesis Cardinal Symptom Index (GCSI) of PAGI-SYM questionnaire. EXCLUSION CRITERIA: 1. Prior gut lumen surgery on the esophagus or the stomach, including Nissen fundoplication. 2. Prior surgery on the pylorus (G-POEM, surgical pyloroplasty, surgical pyloromyotomy) 3. Known history of achalasia or esophageal stricture 4. Known history of physiological or mechanical GI obstruction 5. Abnormalities seen on a prior upper endoscopy placing patient at increased risk: - Ulcer of the esophagus, stomach, or duodenum - Esophageal varices 6. Individuals at risk for prolonging the endoscopy procedure: severe chronic pulmonary disease, severe food retention in the stomach on endoscopy. 7. Presence of significant gastric or duodenal pathology that could be expected to cause dysmotility (e.g. significant inflammation, infiltrate disorders etc) 8. Individuals with a history of other chronic disease potentially causative of gastrointestinal symptom 9. Acute or chronic renal insufficiency 10. Current eating disorders 11. Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to endoscopic procedures. 12. Individuals with contraindications for endoscopy, including bleeding abnormalities 13. Allergy to eggs preventing sedation with propofol and/or gastric emptying test 14. Significant dysphagia 15. Prior inflammatory bowel disease, Crohn's 16. History of any esophageal/gastric/pyloric injection of botulinum toxin 17. Patients on daily opioid use or >3 day/week use 18. Use of glucagon-like peptide 1 (GLP1) receptor agonists or Sodium-Glucose Transport Protein 2 (SGLT2); Gastric inhibitory polypeptide (GIP)- glucagon-like peptide (GLP) combo

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Massachusetts General Boston Massachusetts
United States Texas Tech University Health Science Center (TTUHSC) El Paso Texas
United States University of Louisville Louisville Kentucky
United States Temple University Philadelphia Pennsylvania
United States Mayo Clinic Arizona Scottsdale Arizona
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (8)

Lead Sponsor Collaborator
Johns Hopkins Bloomberg School of Public Health Massachusetts General Hospital, Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Temple University, Texas Tech University Health Sciences Center, El Paso, University of Louisville, Wake Forest University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Desipio J, Friedenberg FK, Korimilli A, Richter JE, Parkman HP, Fisher RS. High-resolution solid-state manometry of the antropyloroduodenal region. Neurogastroenterol Motil. 2007 Mar;19(3):188-95. doi: 10.1111/j.1365-2982.2006.00866.x. — View Citation

Fisher R, Cohen S. Physiological characteristics of the human pyloric sphincter. Gastroenterology. 1973 Jan;64(1):67-75. No abstract available. — View Citation

Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986 Jun;90(6):1919-25. doi: 10.1016/0016-5085(86)90262-3. — View Citation

Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov;127(5):1592-622. doi: 10.1053/j.gastro.2004.09.055. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Distensibility of the pylorus Distensibility of the pylorus will be calculated as the median of three measurements (not three different inflations) of distensibility (mm2/mmHg) of the pylorus pressure using the Endoflip balloon catheter at 50 mL volume Baseline
Secondary Opening diameter (mm) of the pylorus when 40 mL volume is introduced into the EF325N Endoflip™ measurement catheter. diameter (mm) of the pylorus Baseline
Secondary Opening diameter (mm) of the pylorus when 50 mL volume is introduced into the EF325N Endoflip™ measurement catheter. diameter (mm) of the pylorus Baseline
Secondary Cross Sectional Area(mm2) of the pylorus with 40 mL balloon volume Cross Sectional Area (mm2) of the pylorus Baseline
Secondary Cross Sectional Area(mm2) of the pylorus with 50 mL balloon volume Cross Sectional Area (mm2) of the pylorus Baseline
Secondary Compliance (mm3/mmHg) of the pylorus with 40 mL balloon volume Compliance (mm3/mmHg) of the pylorus Baseline
Secondary Compliance (mm3/mmHg) of the pylorus with 50 mL balloon volume Compliance (mm3/mmHg) of the pylorus Baseline
Secondary Pressure (mmHg) of the pyloric sphincter Pressure (mmHg) of the pyloric sphincter Baseline
See also
  Status Clinical Trial Phase
Completed NCT03941288 - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Phase 2
Terminated NCT03285308 - A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase 3
Completed NCT00733551 - Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects. Phase 1
Completed NCT01650714 - Endoscopic Full Thickness Biopsy, Gastric Wall. N/A
Completed NCT01452815 - Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis Phase 2
Completed NCT01039974 - GSK962040 Drug-drug Interaction Study With Ketoconazole Phase 1
Terminated NCT04844190 - Use of EndoFLIP and Manometry Prior to G-POEM N/A
Enrolling by invitation NCT06215547 - Medtronic Enterra II Neurostimulator N/A
Completed NCT04026997 - A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis Phase 2
Completed NCT00562848 - A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040 Phase 1
Enrolling by invitation NCT04207996 - Vagus Nerve Response in Gastroparesis Patients
Completed NCT04607304 - ABCA2 GIRMS Analytical Validation Clinical Performance Study N/A
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Completed NCT03259841 - Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
Active, not recruiting NCT04300127 - Pioglitazone for Idiopathic Gastroparesis Early Phase 1
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Terminated NCT04635306 - 13C-Spirulina Nitrogen Content GEBT Study N/A
Withdrawn NCT02420925 - Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis N/A
Recruiting NCT00777439 - Domperidone for Refractory Gastrointestinal Disorders N/A
Terminated NCT00760461 - Domperidone in Refractory Gastroparesis Phase 2